Targeting glucose control and managing cardiovascular (CV) risk factors may prevent future CV events, and have positive downstream impact by reducing costs to healthcare stakeholders.
Jennifer Kim, PharmD
Advertisement
Articles by Jennifer Kim, PharmD
The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
Advertisement
Latest Updated Articles
- Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease
Published: March 18th 2015 | Updated:
- Metastatic Non–Small Cell Lung Cancer: Costs Associated With Disease Progression
Published: September 15th 2008 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
White House to Announce Second Drug Pricing Deal as AstraZeneca Joins TrumpRx
5
